One patient showed a transient response to CD19 CAR-T cell therapy, probably due to CD19 CAR-T cells not expanding adequately, so he received CD22 CAR-T cell therapy as soon as the tumor regrowth was detected. This evidence concerns the gene CD22 and neoplasm.